This Leading Pharma Stock is in focus as it reported its Q4 FY25 results, where it reported robust operational performance and declared a 1,500 percent dividend. Following the results, the Stock surged by 6.38 percent.
With a market capitalization of Rs. 1,76,222 Crore, the stock of Divis Laboratories opened at Rs. 6,400, up 1.89 percent from yesterday’s close, and after opening, it made a high of Rs. 6,682, up 6.38 percent. Additionally, the Yearly return for the stock is 65 percent, and the past 5-year return is 186 percent.
Financial Highlights & Dividend Recommendation
The company reported a 12.24 percent YoY increase in revenue from Rs. 2,303 Crore in Q4FY24 to Rs. 2,585 Crore in Q4FY25. On a QoQ basis, the company reported an increase of 11.47 percent in revenue from Rs. 2,319 Crore in the previous quarter.
Their Net profit saw an increase of 23.04 percent YoY from Rs. 538 Crore to Rs. 662 Crore for the same period. On a QoQ basis, the company reported an increase of 12.39 percent in Net profit from Rs. 589 Crore in the previous quarter.
The board has recommended a final dividend of Rs. 30 per share or 1,500 percent compared to the face value of Rs. 2 per equity share. The dividend will be subject to approval at the AGM
Giving an Update on the Capex Programs, the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, has commenced commercial operations in Q4FY25. r. The Company has capitalised assets valuing {1,118 crores during the financial year, of which 755 crores pertaining to Unit-III at Kakinada.
Also read: Defence stock jumps 9% after reporting 153% net profit growth in Q4
About the Company
Founded in 1990 and headquartered in Hyderabad, Divis Laboratories Limited is one of India’s leading pharmaceutical companies, renowned globally for manufacturing high-quality active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients.
The company operates primarily in the custom synthesis and generic API segments, supplying to top global pharma companies. Divi’s has two world-class manufacturing facilities in Andhra Pradesh and Telangana, both of which are USFDA and EU GMP compliant.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
